For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Explore the power of knock-out cell lines for your research

Serological biomarkers for COVID-19

Related

  • Cytokine storm in COVID-19
    • SARS-CoV-2 cell entry mechanism
      • SimpleStep ELISA for COVID-19 webinar
        • Top tips to resume research post-COVID-19
          • Abcam China's emergence from COVID-19
            • Biomarker profiling for the clinic webinar
              • SARS-CoV-2 spike protein antibody in research
                • Maximize research efficiency on return to the lab
                  • Quality recombinant SARS-CoV-2 proteins
                    • SARS-CoV-2 infection serology
                      • Cell engineering products for COVID-19

                        Establishing clinical biomarkers for COVID-19 could help clinicians identify the onset of severe disease earlier, improve prognosis and stratify patients to support treatments.

                        Updated May 19, 2022.

                        Serological biomarkers offer a measure of an individual's biochemistry, from a simple patient blood sample, that can help quantify health and disease. The majority of biomarker research and diagnostics have used ELISAs for rapid and quantifiable bioassays from small volumes of patient samples, with the ability to easily adapt this technology to automation and high throughput screening. 

                        While COVID-19 typically manifests as a respiratory tract infection, some patients experience more severe pathologies, including acute respiratory distress syndrome, lung injury, shock and multiple organ failure. In addition to the involvement of the respiratory system, increasing research indicates that coagulation abnormalities and hyper-inflammatory responses are features of severe cases of COVID-19, with a range of serological indicators that could act as viable biomarkers for disease outcomes.

                        Coagulopathy biomarkers

                        COVID-19 is associated with frequent thrombotic events at both the micro- and macro-vascular levels due to hypercoagulability. So-called ‘COVID-19 associated coagulopathy’ (CAC) represents a key factor in organ damage resulting from COVID-19.1-4 Both retrospective and prospective studies have highlighted elevated levels of coagulatory proteins in patients with severe COVID-19 compared to non-severe cases. The most commonly identified coagulopathy biomarkers are elevated D-dimer levels, thrombocytopenia, elevated fibrinogen levels, platelet count reduction and a mildly prolonged prothrombin time.1

                        In an early 2020 study, for example, patients with D-dimer levels over 1 µg/mL (standard range <250 ng/mL) showed an 18-fold increased risk of death.2 Thrombocytopenia has been negatively correlated with COVID-19 severity in some studies.2 However, other analyses have suggested that true thrombocytopenia, low platelet count, is only present within 5% of patients, while mild thrombocytopenia was observed in 70-95% of severe COVID-19 cases.1

                        Together these factors of thrombocytopenia, elevated D-dimer and increased prothrombin time have implicated disseminated intravascular coagulation (DIC). Still, the biomarker levels observed in COVID-19 are not reflective of those seen in other conditions, such as sepsis, which also cause DIC. In comparison to sepsis-induced DIC, COVID-19-induced DIC shows much higher levels of D-dimer and reduced levels of thrombocytopenia.1 With CAC, in fact, high levels of D-dimer are found, but also high levels of fibrinogen and only minimal variations in platelet count and PT compared to SIC and DIC, thus missing the typical characteristic of ‘consumption coagulopathy’.4

                        Kawasaki disease (KD) has also been associated with SARS-CoV-2 infection in children.5-6 KD symptoms include multisystem inflammation,7,8 and various studies have indicated that D-dimer, troponin and BNP levels may be elevated in COVID-19-related Kawasaki disease. As it stands, the association and triggers of KD-associated COVID-19 are poorly understood, necessitating further research.​

                        Other markers of coagulopathy in COVID-19 include elevated lactate dehydrogenase and ferritin levels. These have been observed across several patient cohorts and indicate thrombotic microangiopathy, which has been seen in some severe cases of COVID-19 post-mortem.1

                        Inflammatory biomarkers

                        Hyperactivation of the inflammatory cascade, leading to cytokine storm, has been extensively cited as a critical response in patients with severe COVID-19. The most significantly elevated inflammatory cytokines of severe COVID-19 are thought to be TNF-α, IL-1, IL-6 compared to non-severe disease cases.1, 10-12

                        Studies also show an increase in C-reactive protein (CRP) levels associated with more severe forms of COVID-19 and hospitalization.3,4 Elevated CRP was also identified by researchers investigating COVID-19 related Kawasaki disease, with patients exhibiting both elevated CRP and ferritin levels.7

                        Blood-type biomarkers

                        ABO blood types have been linked to various conditions, such as blood group O being protective for cardiovascular disease and thrombosis risk. In COVID-19 analysis of ABO blood types has shown a further protective role for blood type O.13, 14 ABO antigens are expressed on epithelial cells, platelets, erythrocytes and the blood glycoproteins, von Willebrand factor (VWF) and Factor VIII. Cases of severe pneumonia in COVID-19 patients have been associated with higher levels of both VWF and Factor VIII, and individuals with blood type O have previously been shown to exhibit 20-30% lower levels of VWF compared to non-O type individuals.13

                        ​​SimpleStep ELISA® for serological biomarkers

                        Validation of serological biomarkers for COVID-19 could improve patient care and disease outcomes for severe cases. As many of the biomarkers under investigation are commonly elevated in other conditions, assays that target these factors are often already in existence and could be adapted for COVID-19 research. Our range of SimpleStep ELISA® kits target many of these potential biomarkers and deliver results in just 90 minutes with a simple single-wash protocol for minimal hands-on lab time. Developed with our own in-house recombinant matched antibody pairs, these rapid ELISA kits offer continuity of results across platforms and in transitioning research to the clinic.

                        SimpleStep ELISA serological biomarkers

                        A more extensive list of COVID-19 associated serological biomarkers can be found below:15, 16

                        IL-6 | D-Dimer | LDH | CRP | BNP | Troponin | CK | Ferritin | Fibrinogen | AST | PCT | Myoglobin | 
                        ​ AP | Albumin

                        Abcam’s products are intended for research use only, not for use in diagnostic, therapeutic, or any other purposes.


                        References

                        1. Levi, M. et al. (2020) Lancet Haematol. 7(6): e438–e440.
                        2. Sardu, C. et al. (2020) J Clin Med 9(5), 1417
                        3. Kermali, M. et al. (2020) Life Sci 117788.
                        4. Lorini, FL. et al. (2021) European Heart Journal 23(E), E95-98
                        5. Verdoni, L. et al. (2020) Lancet [Epub ahead of publication]
                        6. Loomba, R.S. et al. (2020) Cardiol Young 1-5
                        7. Sample, I. (2020) The Guardian 17 May [https://www.theguardian.com/science/2020/may/17/possible-breakthrough-in-coronavirus-related-syndrome-in-children]
                        8. Jakob, A. et al. (2020) Eur J Paediatr. 179(3):377-384
                        9. Kong, W.X. et al. (2019) World J Paediatr 15(2):168-175
                        10. Chen, L. et al. (2020) Chinese J Tuberculosis Respir Dis 43(0):E005
                        11. Wang, W. et al. (2020) medRxiv [https://doi.org/10.1101/2020.02.26.20026989]
                        12. Ruan, Q. et al. (2020) Intensive Care Med. 46(5):846-848
                        13. O’Sullivan, J.M. (2020) British J Haematol [https://doi.org/10.1111/bjh.16845]
                        14. Ellinghaus, D. et al. (2020) medRxiv [doi:https://doi.org/10.1101/2020.05.31.20114991]
                        15. Sheth, A. et al. (2021). Nat Sci Rep 11(4930)
                        16. Wang, F. et al. (2020). JCI Insight 5(10)​





                        Get resources and offers direct to your inbox Sign up
                        A-Z by research area
                        • Cancer
                        • Cardiovascular
                        • Cell biology
                        • Developmental biology
                        • Epigenetics & Nuclear signaling
                        • Immunology
                        • Metabolism
                        • Microbiology
                        • Neuroscience
                        • Signal transduction
                        • Stem cells
                        A-Z by product type
                        • Primary antibodies
                        • Secondary antibodies
                        • Biochemicals
                        • Isotype controls
                        • Flow cytometry multi-color selector
                        • Kits
                        • Loading controls
                        • Lysates
                        • Peptides
                        • Proteins
                        • Slides
                        • Tags and cell markers
                        • Tools & Reagents
                        Help & support
                        • Support
                        • Make an Inquiry
                        • Protocols & troubleshooting
                        • Placing an order
                        • RabMAb products
                        • Biochemical product FAQs
                        • Training
                        • Browse by Target
                        Company
                        • Corporate site
                        • Investor relations
                        • Company news
                        • Careers
                        • About us
                        • Blog
                        Events
                        • Tradeshows
                        • Conferences
                        International websites
                        • abcam.cn
                        • abcam.co.jp

                        Join with us

                        • LinkedIn
                        • facebook
                        • Twitter
                        • YouTube
                        • Terms of sale
                        • Website terms of use
                        • Cookie policy
                        • Privacy policy
                        • Legal
                        • Modern slavery statement
                        © 1998-2022 Abcam plc. All rights reserved.